Short answer
Tango Therapeutics, Inc. (TNGX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Executive Chair Barbara Weber departed August 3, 2026 and resigned from Tango’s board and all officer positions.
Tango Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Executive Chair Barbara Weber departed August 3, 2026 and resigned from Tango’s board and all officer positions
- Departure unrelated to disagreements over operations, practices, or policies
- Separation benefits include salary continuation through December 31, 2026 and COBRA reimbursement
- Equity vesting accelerates by 12 months, with eligible option exercise extended through August 3, 2027
- Potential 2026 prorated incentive compensation payable by March 15, 2027, subject to performance and separation agreement execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tango Therapeutics, Inc. 8-K filings
Get the next TNGX 8-K as it lands
Follow TNGX for push alerts, or ask the research agent what this filing means.